Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001698530-24-000150
Filing Date
2024-12-26
Accepted
2024-12-26 16:25:14
Documents
15
Period of Report
2024-12-20
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A xcur-20241220.htm   iXBRL 8-K/A 24560
2 EX-99.1 ex991pressrelease122124.htm EX-99.1 9316
6 exicureimage1a10.gif GRAPHIC 2794
  Complete submission text file 0001698530-24-000150.txt   165887

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xcur-20241220.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xcur-20241220_lab.xml EX-101.LAB 22532
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xcur-20241220_pre.xml EX-101.PRE 13047
17 EXTRACTED XBRL INSTANCE DOCUMENT xcur-20241220_htm.xml XML 2708
Mailing Address 2430 N. HALSTED ST. CHICAGO IL 60614
Business Address 2430 N. HALSTED ST. CHICAGO IL 60614 847-673-1700
EXICURE, INC. (Filer) CIK: 0001698530 (see all company filings)

EIN.: 815333008 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39011 | Film No.: 241581339
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)